Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 5/2002

01-12-2002 | Case Report

Absence of Clinical Prognostic Value of Vascular Endothelial Growth Factor and Microvessel Density in Multiple Myeloma

Authors: Jung-Hye Choi, Myung-Ju Ahn, Se-Jin Jang, Chan-Kum Park, Yong-Wook Park, Ho-Suk Oh, Young-Yuel Lee, Il-Young Choi, In-Soon Kim

Published in: International Journal of Hematology | Issue 5/2002

Login to get access
Metadata
Title
Absence of Clinical Prognostic Value of Vascular Endothelial Growth Factor and Microvessel Density in Multiple Myeloma
Authors
Jung-Hye Choi
Myung-Ju Ahn
Se-Jin Jang
Chan-Kum Park
Yong-Wook Park
Ho-Suk Oh
Young-Yuel Lee
Il-Young Choi
In-Soon Kim
Publication date
01-12-2002
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2002
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/BF02982812

Other articles of this Issue 5/2002

International Journal of Hematology 5/2002 Go to the issue

OriginalPaper

Combination of Chemotherapy and Monoclonal Antibodies for the Treatment of Lymphoma

OriginalPaper

Intensified Daunorubicin in Induction Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Postremission Therapy (Double-7 Protocol) for Adult Acute Myeloid Leukemia

Case Report

Intensive Plasma IgG Removal Therapy for Severe Thrombotic Thrombocytopenic Purpura

OriginalPaper

Constitutive Activation of C-kit by the Juxtamembrane but Not the Catalytic Domain Mutations Is Inhibited Selectively by Tyrosine Kinase Inhibitors STI571 and AG1296

OriginalPaper

The Control of Expression of the α-Globin Gene Cluster

Case Report

Comparison of Microvessel Density Before and after Peripheral Blood Stem Cell Transplantation in Multiple Myeloma Patients and Its Clinical Implications: Multicenter Trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits